AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

ImStem Biotechnology to Launch Phase 1 Trial Testing IMS001 for MS